Literature DB >> 29869138

If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis.

Emma P Deloughery1, Vinay Prasad2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29869138      PMCID： PMC6082210          DOI： 10.1007/s11606-018-4498-3

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  2 in total

1.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

2.  Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study.

Authors:  Luis C L Correia
Journal:  Arq Bras Cardiol       Date:  2016-03       Impact factor: 2.000
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.